Current pharmacotherapy of rosacea

Czech version

Authors: Magdalena Ryšavá ¹; Renata Žáková ²
Authors‘ workplace: Pracoviště klinické farmacie, Nemocnice Milosrdných bratří, Brno ¹; Úsek klinické farmacie, Lékárna Nemocnice Jihlava ²
Published in: Čes. slov. Farm., 2024; 73, 156-162
Category: Current Pharmacotherapy
doi: https://doi.org/10.36290/csf.2024.024

Overview

Up to one-fifth of patients in GP surgeries have skin diseases. One of the most serious is rosacea, which can significantly reduce quality of life and increase the incidence of psychosocial disorders (depression, anxiety, social isolation) in patients with this disease. The prevalence of the disease is reported to be around 10 %. Successful dermatological treatment of rosacea is a complex process involving a correct diagnostic assessment, choosing an appropriate therapeutic approach for the patient. It is mainly guided by the severity of symptoms, the psychological impact on the patient and the compliance to treatment. Primarily, provocative factors should be reduced, and dermocosmetics available in the pharmacy can be used as a supportive and complementary treatment. The results of pharmacological treatment are often unsatisfactory.

Keywords:

rosacea – facial erythrosis – dermatosis – dermocosmetics.

Sources

1. Harper J. Rosacea Linked To A Higher Risk Of Parkinson’s And Alzheimer’s Diseases. In: mayoclinic.org (Internet). 2016. (cited 2024-04-05). Available from: https://www.rosacea.org/rosacea-review/2016/summer/rosacea-linked-to-a-higher-risk-of-parkinsons-and-alzheimers-diseases.

2. Egeberg A, Hansen RP, Gislason HG et al. Patients with rosacea have increased risk of dementia. Ann Neurol. 2016;79(6): 921-928.

3. Choi D, Choi S, Park SM et al. Association of Rosacea With Cardiovascular Disease: A Retrospective Cohort Study. J Am Heart Assoc. 2021;10(19):1-10.

4. Lazaridou E, Korfitis CH, Kemanetzi CH et al. Rosacea and Helicobacter pylori: links and risks. Clin Cosmet Investig Dermatol. 2017;10:305-310.

5. Jørgensen AR, Egeberg A, Gideonsson R et al. Rosacea is associated with Helicobacter pylori: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(12):2010-2015.

6. Yang X. Relationship between Helicobacter pylori and Rosacea: review and discussion. BMC Infect Dis. 2018;18(1).

7. Kim JH, Min JH; Jo YW et al. Association Between Acid-Suppressive Drugs and Risk of Rosacea: Retrospective Study Using the Korean National Health Insurance Service-National Sample Cohort. J Korean Med Sci. 2023;38(47).

8. Mills CM, Marks R. Environmental factors influencing rosacea. Clin Exp Dermatol. 1996;21(2):172-3.

9. Geng RSQ, Bourkas AN, Mufti A et al. Rosacea: Pathogenesis and Therapeutic Correlates. J surg med. 2024;28(2):178-189.

10. Nevoralová Z. Léčba akné a růžovky v těhotenství. Remedia. 2018;(28)6;590-595.

11. Krajsová I. Úspěšná terapie kožních onemocnění vyžaduje komplexní přístup. Remedia. 2017; 27(3):216

12. Rosacea (Internet). Mayo Clinic Health Library; c2024 (cited 2024-04-05). Available from: https://www.mayoclinic.org/diseases-conditions/rosacea/diagnosis-treatment/drc-20353820.

13. Pánková R. Rosacea. Dermatol praxi. 2017;11(1):6-11.

14. Ludmann P. Rosacea: Overview. In: aad.ord (Internet). 2024. (cited 2024-04-05). Available from: https://www.aad.org/public/diseases/rosacea/what-is/overview.

15. Benáková N. Rosacea. Čes-slov Derm. 2018;93(2):79.

16. Kafka V. Ekzémy, Rosacea. In: Akademie Pierre Fabre Dermo-Cosmétique: 55. cyklus. Feb 2024. Brno.

17. Rosacea (růžovka) a kuperóza – Poznejte příznaky onemocnění včas a najděte řešení. (Internet). 2024. (cited 2024-05-07). Available from: https://www.eucerin.cz/o-kuzi/indikace/rosacea.

18. Gallucio G, D’Onghia M, Malvaso D et al.: A Phenotype-Based Therapeutic Approach. Cosmetics. 2024;11(1).

19. Semenescu I, Similie D, Diaconeasa Z et al. Recent Advances in the Management of Rosacea through Natural Compounds. Pharmaceuticals. 2024;17(2):212.

20. Jiawen Z, Peiyu J, Lei Sheng et al. A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages. Front. immunol. 2021;12.

21. Assiri A, Hobani AH, AlKaabi HA et al. Efficacy of Low-Dose Isotretinoin in the Treatment of Rosacea: A Systematic Review and Meta-Analysis. Cureus. 2024;16(3).

22. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;46(6):961-965.

23. Reinholz M., Tietze JK, Kilian K et al. Rosacea – S1 Guideline. JDDG. 2013;11(8):768-780.

24. Ihrisky SA. Rozacea – současný pohled. Čes-slov Derm. 2018;93(5):163–173.

25. Pelle MT, Crawford GH, RAWFORD, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499-512.

26. Majer LE, Helfrich YR. Rosacea: Pathogenesis, clinical features, and diagnosis. In: UpToDate. 2022, 03-2024. Dostupné z: https://www.uptodate.com/contents/rosacea-pathogenesis-clinical-features-and-diagnosis?sectionName=CLINICAL+FEATURES & search=rosacea & topicRef=16632 & anchor=H432867 & source=see_link#H432867. (cit. 2024-04-05).

27. Maier L. E. Management of rosacea. Online. UpToDate. 2022, 03-2024. Dostupné z: https://www.uptodate.com/contents/management-of-rosacea?search=rosacea & source=search_result & selectedTitle=2%7E124 & usage_type=default & display_rank=1. (cit. 2024-04-05).

28. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50(1):107-8.

29. Nevoralová Z. Léčba Rosacey. Remedia. 2017; 27(3):219-225.

30. Sobolewska B, Doycheva D, Deuter C et al. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33(3):257-60.

31. Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015;41(1):9-16.

32. Dwayebová R. Local therapy of inflammatory (papulopustular) lesions of rosacea in adult patients. Dermatol praxi. 2018;12(4):164-166.

33. Slonková V. Rosacea a dermatitis perioralis. Čes-slov Derm. 2008;84(4):183-193.